European Penny Stocks: Transferator And 2 More Companies To Consider

As European markets navigate mixed performances, with the pan-European STOXX Europe 600 Index rising slightly on dovish signals from the U.S. Fed, investors are keeping a close eye on opportunities within smaller market segments. Penny stocks, a term that may seem outdated but still points to potential value in smaller or newer companies, offer intriguing prospects for those willing to explore beyond traditional investments. By focusing on companies with solid financial foundations and potential for growth, investors can uncover hidden value in quality penny stocks across Europe.

Top 10 Penny Stocks In Europe

Click here to see the full list of 278 stocks from our European Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Transferator (NGM:TRAN A)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Transferator AB (publ) is a public private equity and venture capital firm with a market cap of SEK128.41 million.

Operations: The firm generates revenue from its operations in Sweden, amounting to SEK55.43 million.

Market Cap: SEK128.41M

Transferator AB, with a market cap of SEK128.41 million, has shown some financial resilience despite being unprofitable. Recent earnings reports indicate modest revenue growth to SEK15.45 million in Q2 2025, with a net income of SEK0.469 million compared to a loss last year. The company's short-term assets exceed both its short and long-term liabilities, providing some financial stability. However, high volatility persists in its share price and interest payments are not well covered by EBIT. Although trading significantly below estimated fair value, the dividend is unsustainable without adequate earnings or cash flow coverage.

• Click here to discover the nuances of Transferator with our detailed analytical financial health report.
• Gain insights into Transferator's historical outcomes by reviewing our past performance report.

Scandinavian ChemoTech (OM:CMOTEC B)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions in Sweden and Florida, with a market cap of SEK 114.39 million.

Operations: The company generates its revenue primarily from its Medical Products segment, which reported SEK 9.85 million.

Market Cap: SEK114.39M

Scandinavian ChemoTech, with a market cap of SEK 114.39 million, remains a speculative investment due to its pre-revenue status and ongoing unprofitability. Recent strategic alliances, such as the partnership with SLU University Animal Hospital for its Tumour-Specific Electroporation therapy, highlight efforts to expand clinical adoption in veterinary oncology. Despite stable weekly volatility and no debt burden, the company faces cash runway challenges but has raised additional capital through private placements. The share price has been highly volatile recently, and while earnings are forecasted to grow significantly, current financial stability is limited by insufficient short-term asset coverage of liabilities.

• Click here and access our complete financial health analysis report to understand the dynamics of Scandinavian ChemoTech.
• Gain insights into Scandinavian ChemoTech's future direction by reviewing our growth report.

Nordic LEVEL Group AB (publ.) (OM:LEVEL)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Nordic LEVEL Group AB (publ.) offers safety and security solutions mainly in Sweden and has a market cap of SEK124.85 million.

Operations: The company's revenue is primarily derived from its Technology segment, which generated SEK361.71 million, followed by Advisory at SEK19.63 million and Group-wide services at SEK11.54 million.

Market Cap: SEK124.85M

Nordic LEVEL Group AB (publ.) has a market cap of SEK124.85 million and focuses on safety and security solutions, primarily in Sweden. Despite being unprofitable, the company reported a reduced net loss for Q2 2025 compared to the previous year, with revenue at SEK94.58 million. Its debt-to-equity ratio has significantly decreased over five years, indicating improved financial health. Although short-term liabilities exceed assets slightly, long-term liabilities are well covered by assets. The management team is relatively new with an average tenure of 1.4 years, while the board is more experienced with three years on average.

• Unlock comprehensive insights into our analysis of Nordic LEVEL Group AB (publ.) stock in this financial health report.
• Evaluate Nordic LEVEL Group AB (publ.)'s prospects by accessing our earnings growth report.

Taking Advantage

• Embark on your investment journey to our 278 European Penny Stocks selection here.
• Want To Explore Some Alternatives? These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com